ASHP Specialty Drug Information
ASHP Specialty Drug Information (SPDI) contains especially curated content related to specialty drug products, defined as those medications that are used to treat specific rare and/or complex chronic diseases and that generally meet some or all of the following criteria: (1) initiated and maintained by a specialist; (2) self-administered; (3) require an additional level of care in the chain of custody; (4) high cost; (5) unique distribution; (6) extensive or in-depth monitoring and/or patient counseling; and (7) need for reimbursement assistance.
- As of November 2024, SPDI contains content related to approximately 350 medications administered to patients with a variety of specialized or rare disease states.
- Clinical content for each medication within SPDI is provided via an updated AHFS DI and AHFS DI Essential monograph format developed with input from specialty pharmacy practitioners. Ongoing surveillance of FDA new drug approvals, indications, and other major labeling updates is completed to ensure timely content updating.
- ASHP also partnered with the Institute for Safe Medication Practices (ISMP) to offer a Pro-active Risk Assessment for each drug within the SPDI product. These risk assessments provide detailed information on safety concerns; selection, ordering, and procurement; storage and handling; pharmacy order processing and verification; preparation and dispensing; administration and disposal; and shipping and delivery.
- SPDI may be further customizable with the addition of Patient Medication Information monographs and MedGuides.
Benefits
- Requires no pharmacy resources needed to create and maintain information
- Supports compliance with accreditation requirements (URAC)
- Enables consistency throughout the specialty patient care workflow
Contact Us
If you are interested in learning more about our ASHP and AHFS Drug Databases, please complete the Contact Us form and an ASHP representative will be in contact.
ADVERTISEMENT